Your web browser is out of date! We recommend you update your browser to receive the best possible browsing experience.
Pre-order your Brochure
Reserve your place

16th Annual eyeforpharma Philadelphia 2018 10 - 11 April, 2018|Philadelphia, US

Industry Leaders who shared their insights with us in 2017...

Kabir Nath

Kabir Nath

President & CEO, Otsuka North America

Read more

Kabir is a senior commercial leader with more than 25 years of broad international biopharma and devices experience who has shaped strategy and delivered results in complex, challenging business environments at country, regional and global levels. He has lived and worked in the U.K., France, Spain, India, Singapore, China and the US.

Kabir joined Otsuka to head the North American pharmaceutical business in March 2016, with direct responsibility for Otsuka America Pharmaceuticals, Inc., Avanir and Otsuka Canada. Before joining Otsuka, Kabir spent 13 years in leadership roles at Bristol Myers Squibb. Most recently he was Senior Vice President, Virology, Transplant & Optimized Brands, responsible for the commercialization of a significant portfolio – including drugs for HIV, hepatitis B and hepatitis C and immunosuppression - in the USA.

Previously he was Senior Vice President, Global Commercialization - Virology & Neuroscience, leading global strategy for these two disease areas. In addition he served as interim head of Emerging Markets for much of 2012.

Kabir joined BMS in Singapore in 2003 as vice president for South East Asia/Taiwan/HK and moved to Shanghai in 2005 as president of BMS China. In 2008, Kabir was appointed president, Asia Pacific Medicines, with responsibility for all commercial operations in 13 countries. Prior to joining BMS, Kabir spent 11 years at Smith & Nephew, the medical technology company, in senior operational and strategic roles in the U.K., Europe and Asia. Kabir holds an MA from King’s College, University of Cambridge, and an MBA with Distinction from INSEAD.

Andy Schmeltz

Andy Schmeltz

Senior Vice President of Patient & Health Impact, Pfizer Innovative Health

Read more

More information coming soon...

Julie Gerberding

Julie Gerberding

Executive VP & Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health, Merck

Read more

Dr. Julie Gerberding is Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy, and Population Health at Merck & Co., Inc., where she also has responsibility for the “Merck for Mothers” global program to prevent maternal mortality and the Merck Foundation. She joined Merck in January 2010 as president of Merck Vaccines and led efforts to make the company’s vaccines more available and affordable to people in resource-limited countries around the world.

She left her tenured faculty position at the University of California, San Francisco in 1998 to lead the U.S. Centers for Disease Control and Prevention (CDC) Division of Healthcare Quality Promotion and then served as the CDC Director from 2002 to 2009. As director, she led the CDC through more than 40 emergency responses to public health crises, including anthrax bioterrorism, SARS, and natural disasters.  She also advised governments around the world on urgent issues such as pandemic preparedness, AIDS, antimicrobial resistance, tobacco, and cancer.

Dr. Gerberding currently serves on the Boards of CWRU, National Association of City and County Health Officials (NACCHO) Foundation, MSD Wellcome Trust Hilleman Laboratories, and the BIO Executive Committee.  She has received more than 50 awards and honors, including the United States Department of Health and Human Services (DHHS) Distinguished Service Award for her leadership in responses to anthrax bioterrorism and the September 11, 2001 attacks.  She was named to Forbes Magazine's 100 Most Powerful Women in the World in 2005 through 2008 and to TIME Magazine's 100 Most Influential People in the World in 2004.

Perry Sternberg

Perry Sternberg

EVP & Head U.S. Commercial, Shire

Read more

Perry joined Shire in 2013 and is head of Shire’s U.S. Commercial Organization. He is also a member of the Executive Committee.

Perry previously was Vice President & General Manager, U.S. & Canada Pharmaceuticals at Bausch & Lomb. Prior to that, he held various roles at Novartis Ophthalmics, Novartis Pharmaceuticals and Merck & Co., Inc.

Sheldon Koenig

Sheldon Koenig

SVP and Global Head Cardiovascular Franchise, Sanofi

Read more

Sheldon has a enjoyed a successful career of more than 25 years in various operations and marketing roles at Merck & Company and has now for the past year been with Sanofi Pharmaceuticals as Sr. VP and Head of the Cardiovascular Franchise. Sheldon has a broad range of experience in Cardiovascular marketing as well as developing product launch strategies in CV and infectious disease as well as several joint venture experiences and licensing agreements in several therapeutic areas. Sheldon received his MBA from Monmouth University and is undergraduate degree in accounting from Drexel University with post graduate and executive education studies completed at Wharton.

David Blair

David Blair

Head of Industry- Health, Google

Read more

David Blair is Head of Industry for Health at Google. He leads a team that provides thought leadership, digital marketing strategies, insights, and cross-platform advertising solutions utilizing Google’s search, content network, YouTube, mobile, programmatic and analytics platforms for the world’s leading pharmaceutical and consumer health companies. Prior to Google, David was General Manager/SVP of Provider Solutions at Everyday Health.

David began his digital career in 1997 at iVillage as Vice President of Strategic Sponsorships where he pioneered many of the first digital marketing initiatives with Fortune 500 companies including P&G, Coke, Ford, Kimberly Clark, Kellogg’s and Fuji Film. He moved into the digital health space in 2001 as SVP/Group Publisher for Johnson & Johnson’s BabyCenter.com and was SVP of Ad Sales for Revolution Health, before the merger with Everyday Health in 2008.

Blair serves on the Google Healthcare Advisory Board, was named one of the top 40 Healthcare Transformers in the US by Medical Marketing & Media in 2015 and was a juror for the 2016 Clio Health Awards. He is a frequent keynote speaker at major agencies and industry events, most recently the IMCAS World Congress; Cannes Lions Health, American Heart Association, and Cleveland Clinic’s Patient Experience Summit.

Melinda Richter

Melinda Richter

Head, Johnson & Johnson Innovation, JLABS

Read more

As Head of Johnson & Johnson Innovation JLABS, Melinda fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage. By providing infrastructure, services, educational programs and networks in global hotspots, JLABS is the best place to start a biotech company.

Prior to joining JLABS, Melinda was Founder and CEO of Prescience International, an award winning firm dedicated to accelerating research to the patient. Melinda founded Prescience after she had a medical emergency that left her questioning the efficiency and efficacy of the healthcare system. With the tenacity and resolve of a patient looking for a better solution, she set-out to create a better model, which now forms the basis for JLABS’ operational infrastructure. Prior to starting Prescience, Melinda held posts across a variety of functional areas with a global corporation, Nortel Networks, in locations such as Research Triangle Park, New York, Toronto, London, Hong Kong and Beijing before arriving in San Francisco. She also started, raised capital and did large corporate deals for several companies in both the life science and technology space. She holds a Bachelor of Commerce from the University of Saskatchewan in Canada and an MBA from INSEAD in France.

Marc Boutin

Marc Boutin

CEO, National Health Council

Read more

Marc Boutin is the chief executive officer of the National Health Council, the only organization that brings together all segments of the health community to provide a united voice for the more than 133 million people with chronic diseases and disabilities and their family caregivers.

Boutin has been a leading voice for greater patient involvement at every stage of the continuum, starting with the development of new drugs, to regulatory oversight of health care delivery, to shared decision-making at the point of care. Under his leadership, the NHC has convened a broad range of stakeholders to create and effectively implement pragmatic strategies and public policy that address diverse issues, such as enhancing patient engagement, advancing the development of new treatments, and developing a better health delivery system to meet the needs of people with chronic conditions.

Tolga Tanguler

Tolga Tanguler

Regional President, North America, Rare Disease, Pfizer

Read more

Tolga Tanguler is the Regional President, North America for Rare Diseases at Pfizer. In this role, Tolga sets forth an agenda that brings together the marketing, sales, corporate affairs and medical affairs teams to ensure they are focused on one objective: to transform patients’ lives. A key focus of the organization is to ensure that the engagement and experience of rare disease patients and their families is at the forefront of all programs.

Tolga has more than 17 years of experience in the global pharmaceutical industry, including leadership roles in both well-developed markets such as the US, Japan and the Nordics to emerging economies including Africa/Middle East and Latin America. Most recently, Tolga was the Vice President, Global Marketing for ELIQUIS. Throughout these various assignments, Tolga’s organizations were recognized for their strong growth trajectories and their colleague engagement programs.

Tolga has Bachelor of Science degrees in Economics & Finance from University of Istanbul, and a Masters of Business Administration in Marketing and Supply Chain from Michigan State University. He also has a Post Graduate Degree in Marketing from the University of California.

Andrew McCulloch

Andrew McCulloch

President, Kaiser Foundation Hospitals and Kaiser Permanente Health Plan of the Northwest

Read more

Since 2006, Andrew R. McCulloch has served as president of Kaiser Foundation Hospitals and Health Plan of the Northwest. Serving the states of Oregon and Washington, Kaiser Permanente provides medical care to over 550,000 members, along with a dental program serving over 250,000 members.

Under Andy’s leadership, Kaiser Permanente’s Northwest Region is consistently ranked as one of America’s highest performing health systems. Medicare has awarded the Northwest Region’s Medicare Advantage plan its coveted 5 Star rating for 5 consecutive years. The National Commission of Quality Assurance (NCQA) gave Kaiser Permanente Northwest’s Medicare and commercial plans the highest rating in the region in its most recent national survey results.

In the areas of customer service and community benefit, Kaiser Permanente is also recognized for its performance. In 2016— for the third year in a row — J.D. Power ranked Kaiser Permanente’s Health Plan #1 in customer satisfaction for Oregon and Washington. The Portland Business Journal has ranked Kaiser Permanente as #1 in corporate philanthropy for 2014 and 2015.

Andy received his B.A. from Wesleyan University and attended the University of Minnesota’s School of Public Health, where he received a master’s degree in Healthcare Administration. In 2015, Minnesota’s School of Public Health awarded Andy the Gaylord W. Anderson MD Leadership Award, recognizing his leadership in the field of public health. He is a Fellow of the American College of Healthcare Executives, which awarded him its Regent’s Award recognizing his contributions to the field of health care administration. In 2016, Andy was named as one of the Portland Business Journal’s top 10 ‘Executives of the Year’ for leading Kaiser Permanente Northwest’s membership growth while navigating Oregon’s health care industry.

Prior to joining Kaiser Permanente, Andy held increasingly responsible executive roles at the University of North Carolina Health Care System, UW Medicine, PeaceHealth, and Mercy Health.

Andy is also active in a number of professional and civic organizations. He has a special interest in health equity issues. He has served as a founding member of Health Share of Oregon, a coordinated care organization serving Oregon’s Medicaid population. In recognition of his leadership in transforming Oregon’s health care financing and delivery, the Oregon Business Association named him as their Statesman of the Year in 2012.

Andy and his wife, Sally, reside in Lake Oswego, Oregon.

Eddie Williams

Eddie Williams

Former SVP Biopharmaceuticals, Novo Nordisk

Read more
  • 36 years Pharmaceutical Industry experience
  • General Management Experience including P&L
  • 13+ Years of Specialty Biotech Experience
  • Bachelor’s degree in Biology/Chemistry from Marshall University
  • Advisory Board of National Sales Network
  • Chairperson of Capital Campaign of Boys & Girls Club of Trenton/Mercer for new facility
  • Board of Directors of Basic Supply Co., a small family-owned business of 35 years
  • Chair of National Hemophilia Foundation’s (NHF) Industry Advisory Panel
  • Board Member of BIO
  • Numerous internal Global Boards: Global Strategy and Commercial Boards (HSB & HCB), Global Marketing Board (GMB), Global Management Board (ManBoard), North American Executive Team (ET), Global Steering Committee for Business Development and Acquisitions
  • Executive Sponsor for Women in Novo Nordisk (WiNN)
  • Drove Franchise from $500m to $1.7B
  • All performance ratings of “Outstanding or Exceeds” by 6 different President/CEOs/SVPs over 13+ years
  • Market leadership in all 3 therapeutic areas
  • Drove 15+ year old product from 7% to > 50% share and #1 position in crowded 7-product commodity market
  • TBL: Chairperson of B&G Club fundraiser for new facility to raise $7.5M
  • Recognized as the Global “General Manager of the Year” at Novo Nordisk International GM Meeting
  • Awarded the “WE Upjohn Award“, the most prestigious global company performance award
  • Awarded “Lifetime Achievement Award“ by the National Sales Network
  • Recognized as “Industry Partner of the Year“ by National Hemophilia Foundation
  • Leadership Style and success highlighted in 2 published books by independent authors
Dalvir Gill

Dalvir Gill

CEO, Transcelerate BioPharma Inc.

Read more

Dr. Dalvir Gill currently serves as the Chief Executive Officer of TransCelerate BioPharma Inc., and its subsidiary, BioCelerate. TransCelerate is a non-profit organization with a mission to collaborate across the biopharmaceutical research and development community to identify, prioritize, design and facilitate the implementation of solutions to drive efficient, effective and high-quality delivery of new medicines, improving the health of people around the world.

Dr. Gill is a member of the TransCelerate Board of Directors, and spearheads a culture of collaboration amongst TransCelerate’s 19+ Member Companies, and an aggressive agenda that seeks to advance innovation in R&D, identify and solve common R&D challenges and further improve patient safety, with the goal of delivering more high quality medicines to patients.

Prior to his appointment as CEO of TransCelerate, he was the President of an international contract research organization. Dr. Gill earned his BSc in Applied Biology from the University of Hertfordshire and his PhD in Pathobiology from the Royal Free Hospital School of Medicine, University of London. He also holds a diploma in the Health Economics of Pharmaceuticals from the executive program of the Stockholm School of Economics. Dr. Gill has presented his research and spoken at numerous conferences, and has authored more than 30 scientific publications. He also is an elected fellow of the Royal Society of Medicine.

Patrick Desbiens

Patrick Desbiens

Senior Vice President US Vaccines, GSK

Read more

Patrick Desbiens leads GSK’s vaccines business in the US, bringing more than 25 years of industry insight. Patrick joined the US business in 2015 after serving as President of GSK France for nearly 3 years, overseeing the Pharma and Vaccines businesses and all GSK operations there. Previously he led the Sales & Marketing pharma teams in France and also served as General Manager for GSK Romania. A native French speaker from Montreal, Patrick started his career as a pharma rep with Eli Lilly-Canada before joining GSK Canada in 1996 where he worked across several functions in sales, marketing, communications, market access and public affairs.

Paul Darling

Paul Darling

Principle, ZS Associates

Read more

Paul Darling is a principal with ZS in the San Francisco office. Paul assists life sciences companies in evaluating new markets, acquisitions and licensing opportunities, as well as developing new go-to-market strategies. He has published and presented on these topics.

Paul leads ZS's institute on U.S. Healthcare Evolution and Scenario Planning. His work explores strategies for life sciences companies to take a broader role in patient health in the era of U.S. healthcare reform. This includes new business models, therapies, acquisitions, partnerships, and reimagining the commercial model to support such strategies.

Prior to joining ZS, Paul was a fellow at the Perelman School of Medicine at the University of Pennsylvania. He holds a B.S. in biochemistry from Boston College and a Ph.D. in statistical thermodynamics from Washington University.

Pratap Khedkar

Pratap Khedkar

Principle, ZS Associates

Read more

Pratap Khedkar is a managing principal in ZS’s Philadelphia office, and leads the firm’s global pharmaceuticals and data science practices. He has advised many biopharmaceutical and healthcare companies on a wide range of business issues including commercial strategy, customer-centric marketing, market access, sales compensation and advanced analytics.

A recognized healthcare industry expert, Pratap regularly contributes his insights to publications including The Wall Street Journal, Bloomberg Businessweek, Business Insider, Fortune, Medical Marketing & Media, NPR, Pharmaceutical Executive and others. Currently, his thought leadership work focuses on topics including healthcare policy; life sciences companies’ new commercial and organizational models; and the evolving relationships between patients, providers and payers, and the life sciences organizations that serve them.

Pratap holds a B.S. in computer science from the Indian Institute of Technology, Delhi, and a Ph.D. in computer science from the University of California at Berkeley.

Reagan Tully

Reagan Tully

VP, Strategy and Marketing, McKesson

Read more

Reagan Tully brings over 18 years of experience within the pharmaceutical industry in multiple therapeutic categories, including oncology, virology, vaccines, cardiovascular, respiratory and dermatology. She has led sales, operations, marketing and commercial strategy for multiple top 10 manufacturers, including products from clinical development through end of lifecycle. Currently she serves as VP of Strategy for McKesson Specialty Health, within a division that specializes in manufacturer solutions.

Be the first to see the agenda – Pre-order it here

Full agenda • Speakers • Group Discounts